Comparison of liver biopsy and transient elastography based on clinical relevance

Canadian Journal of Gastroenterology

Volumn 22, Issue 9, 2008, Pages 753-757

  Masuzaki, Ryota ^a   Tateishi, Ryosuke ^a   Yoshida, Haruhiko ^a   Goto, Eriko ^a   Sato, Takahisa ^a   Ohki, Takamasa ^a   Goto, Tadashi ^a   Yoshida, Hideo ^a   Kanai, Fumihiko ^a   Sugioka, Yosuke ^a   Ikeda, Hitoshi ^a   Shiina, Shuichiro ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hepatitis C; Liver biopsy; Liver fibrosis

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PROTHROMBIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ELASTOGRAPHY; ESOPHAGUS VARICES; FEMALE; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

EID: 54849429156     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/306726     Document Type: Article

References (37)

1. Poynard T, Bedossa P, Opolon P Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease-IN Engl J Med 1993;328:1797-801.
3. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up stddy of 384 patients. Gastroenterology 1997;112:463-72.
4. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcitiogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81.
5. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-9.
6. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6.
7. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;29:1311-6.
8. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 2005;3(Suppl 2):S141-3.
9. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36(Suppl 1):S152-60.
10. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
11. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
12. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523-5.
13. Le Calvez S, Thabut D, Messous D, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004;39:862-3.
14. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
15. Qiu Y, Hoshida Y, Kato N, et al. A simple combination of serum type IV collagen and prothrombin time to diagnose cirrhosis in patients with chronic active hepatitis C. Hepatol Res 2004;30:214-20.
16. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36(Suppl 1):S57-64.
17. Castera L, Foucher J, Berter J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 2006;43:373-4.
18. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
19. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-9.
20. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006;55:403-8.
21. Kazemi F, Kettanch A, N'kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesopbageal varices. J Hepatol 2006;45:230-5.
22. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
23. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73.
24. Nahon P, Thabut G, Ziol M, et al. Liver stiffness measurement versus clinicians' prediction or both for the assessment of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2006;101:2744-51.
25. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
26. Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-7.
27. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment. J Viral Hepat 2000;7:268-75.
28. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-16.
29. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Hepatology 2005;42:282-92.
30. Balthazar EJ, Naidich DP, Megibow AJ, Lefleur RS. C-F evaluation of esophageal varices. AJR Am J Roentgenol 1987;148:131-5.
31. Kim YJ, Raman SS, Yu NC, To'o KJ, Jutabha R, Lu DS. Esophageal varices in cirrhotic patients: Evaluation with liver CT. AJR Am J Roentgenol 2007;188:139-44.
32. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
33. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
34. Ratziu V, Charlotte F, Heurtier A, et al; LIDO Study Group. Sampling variability of liver biopsy in, nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
35. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-75.
36. Lawson A, Hagan S, Rye K, et al; Trent HCV Study Group. The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007;47:37-45.
37. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-55.